Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer.

Bookmark(0)

No account yet? Register

We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel […]

» Read more

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

Bookmark(0)

No account yet? Register

External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral […]

» Read more

Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial – A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy.

Bookmark(0)

No account yet? Register

To evaluate health-related quality of life following robotic and open radical cystectomy as a treatment for bladder cancer.Using the Randomized Open versus Robotic Cystectomy (RAZOR) trial population we assessed health-related […]

» Read more

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.

Bookmark(0)

No account yet? Register

The 2019 Briganti nomogram was developed to calculate the risk of lymph node invasion (LNI) and identify prostate cancer (PCa) patients diagnosed with magnetic resonance imaging (MRI)-targeted biopsy who should […]

» Read more

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.

Bookmark(0)

No account yet? Register

To examine rates of Grade Group (GG) 4 downgrading at radical prostatectomy (RP) among men diagnosed with high (HR)- and very-high risk (VHR) prostate cancer (PCa) at biopsy.A pooled cohort […]

» Read more

Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.

Bookmark(0)

No account yet? Register

PSA has limited performance in detecting prostate cancer (PCa). The transcription factor GATA2 is expressed in aggressive PCa. Here we analyzed the predictive value of urine extracellular vesicle (EV) GATA2 […]

» Read more

PSA and PSA Doubling Time Predict Findings on 18F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer.

Bookmark(0)

No account yet? Register

PSMA-targeted 18F-DCFPyL PET/CT may offer superior image quality and sensitivity for the detection of biochemically-recurrent prostate cancer. In this study, we examine the association of Gleason sum, serum prostate specific […]

» Read more

Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.

Bookmark(0)

No account yet? Register

To investigate the association of postdiagnosis body mass index (BMI) and weight change with prostate cancer-specific mortality (PCSM), cardiovascular disease-related mortality (CVDM), and all-cause mortality among survivors of nonmetastatic prostate […]

» Read more

Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.

Bookmark(0)

No account yet? Register

Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive […]

» Read more

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.

Bookmark(0)

No account yet? Register

Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined […]

» Read more

Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.

Bookmark(0)

No account yet? Register

Men with germline mutations in DNA-repair genes have a higher risk of developing prostate cancer. Active surveillance (AS) is the preferred treatment modality for low-risk prostate cancer. However, many fear […]

» Read more

Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.

Bookmark(0)

No account yet? Register

This is the first report of the development and performance of a platform that interrogates small non-coding RNAs (sncRNA) isolated from urinary exosomes (the miR Sentinel™ Tests): the Sentinel™ PCa […]

» Read more

Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer.

Bookmark(0)

No account yet? Register

While guidelines support the use of maintenance BCG(mBCG) for patients with intermediate- and high-risk non-muscle invasive bladder cancer(NMIBC), in an era of BCG shortage we explored the cost-effectiveness of mBCG.A […]

» Read more

Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.

Bookmark(0)

No account yet? Register

The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown.To perform a systematic review of the existing literature on the effectiveness of the different […]

» Read more
1 2 3 12